# Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases

> **NCT05414487** · — · UNKNOWN · sponsor: **Tianjin Medical University General Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Multiple Sclerosis
- Neuromyelitis Optica Spectrum Disorder
- Demyelinating Diseases of the Central Nervous System

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT05414487
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-15
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05414487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05414487, "Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05414487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*